Home / Intelligence / Webinars / COVID-19 Impact on Launch Performance
Available On Demand
How has COVID-19 impacted launch performance and timing?
Pharmaceutical leaders are facing some of the toughest challenges of their careers when it comes to launching in the midst of COVID-19. With so much at stake and so much uncertainty, companies are looking for fact-based insights to power their decision-making.
Trinity has done an in-depth evaluation of the impact of COVID-19 on launch performance and timing. We have compared forecasted/expected revenue to actual revenue for products that launched within six months of COVID-19. We have also explored products that received approval during COVID-19 but have had to delay launch.
Join us to hear the findings and get answers that will help you predict the impact on your product launches.
Key Topics
- Case studies of recently launched products that experienced significant challenges and successes through COVID-19
- Insights into the types of product and market factors that contributed to these successes and challenges
- A review of companies that delayed product launches and the impact of COVID-19 on expected FDA approval dates
Fill out the fields below to view “Webinar: COVID-19 Impact on Launch Performance.”
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
Related Intelligence
Webinars
Learn From the Past – Launch Better Tomorrow
Available On Demand
Whether you are an emerging, mid-tier or large-tier company preparing for launch, this webinar is a must-watch. Join us for an informative webinar as our experts dive into Trinity Life Sciences’ latest white paper, the Trinity Annual Drug Index—an evaluation of commercial performance over three years of 58 novel drugs approved in 2020. Hear from […]
Watch Now
White Papers
Trinity Annual Drug Index
This report, the sixth in our Trinity Drug Index series, outlines key themes and emerging trends in the industry as we progress towards a new world of targeted and innovative products. We provide a comprehensive evaluation of the commercial performance over three years of novel drugs approved by the FDA in 2020, with commercial, therapeutic […]
Read More
Webinars
Trinity Launch Accelerator | Lunch and Learn
Available On Demand
Join Trinity Life Sciences for a virtual lunch and learn where Krista Perry—Partner & Head of Launch Excellence, Curt Staab—Head of Client Development and Tarra Maeshima—Director of New Products & Strategy will demonstrate Trinity Launch Accelerator. Launch project management office (PMO) teams and/or dedicated project manager (PM) resources are critical to enabling Launch Excellence-and the […]
Watch Now